Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

LSR reported for 6 months of 2024 by IFRS

8/28/24 LSRG

ITC reported 6 months 2024 by IFRS

8/28/24 WTCM

Rosseti Siberia reported for 6 6 months of 2024 by IFRS

8/28/24 MRKS

Segezha Group decided to conduct an additional share issue

8/28/24 SGZH

HeadHunter increased its stake in Skillaz to 89.99%

8/28/24 HEAD

Rosseti Center and Volga Region reported for 6 months of 2024 by IFRS

8/28/24 MRKP

Rosseti Center reported for 6 months of 2024 by IFRS

8/28/24 MRKC

Artgen reported for 6 months of 2024 by IFRS

8/28/24 ABIO

SPB Exchange reported for 6 months of 2024 by IFRS

8/28/24 SPBE

RN-West Siberia reported for 6 months of 2024 by RAS

8/28/24 CHGZ